Schistosomiasis-associated pulmonary hypertension: Pulmonary vascular disease: The global perspective

Chest

Volumn 137, Issue 6 SUPPL., 2010, Pages 20S-29S

  Graham, Brian B ^a,e   Bandeira, Angela Pontes ^b,e   Morrell, Nicholas W ^c,e   Butrous, Ghazwan ^d,e   Tuder, Rubin M ^a,e  

^a UNIVERSITY OF COLORADO   (United States)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF KENT   (United Kingdom)

^e Pulmonary Vascular Research Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PRAZIQUANTEL; PROTEIN TYROSINE KINASE INHIBITOR; RESISTIN; RESISTIN LIKE MOLECULE ALPHA; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ADULT; BLALOCK HANLON OPERATION; BLOOD PRESSURE; CASE REPORT; CD4+ T LYMPHOCYTE; CERCARIA (TREMATODE LARVA); DIZZINESS; DYSPNEA; ECHOCARDIOGRAPHY; ENDEMIC DISEASE; FEMALE; GRANULOMATOUS INFLAMMATION; HEART AUSCULTATION; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; HEART SURGERY; HEPATOSPLENOMEGALY; HISTOLOGY; HOSPITAL INFECTION; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; HYPOTENSION; IMMUNE COMPLEX DISEASE; IMMUNE RESPONSE; JUGULAR VEIN; LIFE CYCLE; LIVER FIBROSIS; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG GRANULOMA; MOBILIZATION; OOCYTE; PATHOGENESIS; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PORTAL VEIN; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SKIN INFECTION; SYNCOPE; SYSTOLIC HEART MURMUR; TH1 CELL; THORAX PAIN; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TREE; TRICUSPID VALVE REGURGITATION; UROSEPSIS; VASODILATATION; VIROIDAL PLANT DISEASE;

EID: 77953312910     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-0048     Document Type: Review

References (63)

1. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22(2):358-363.
2. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043-3050.
3. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med. 2007;28(1):23-42.
4. Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144(2):275-285.
5. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 2000;77(1):41-51.
6. Chitsulo L, Loverde P, Engels D. Schistosomiasis. Nat Rev Microbiol. 2004;2(1):12-13.
7. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disabilityrelated outcomes in endemic schistosomiasis. Lancet. 2005;365(9470):1561-1569.
8. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411-425.
9. Ribeiro-dos-Santos G, Verjovski-Almeida S, Leite LC. Schistosomiasis - a century searching for chemotherapeutic drugs. Parasitol Res. 2006;99(5):505-521.
10. Shadan S. Drug discovery: schistosome treatment. Nature. 2008;452(7185):296.
11. Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;(3):CD000053.
12. Botros SS, Hammam OA, El-Lakkany NM, El-Din SH, Ebeid FA. Schistosoma haematobium (Egyptian strain): rate of development and effect of praziquantel treatment. J Parasitol. 2008;94(2):386-394.
13. Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res. 2003;90(supp 1):S3-S9.
14. Li YS, Raso G, Zhao ZY, He YK, Ellis MK, McManus DP. Large water management projects and schistosomiasis control, Dongting Lake region, China. Emerg Infect Dis. 2007;13(7):973-979.
15. Malek EA. Effect of the Aswan High Dam on prevalence of schistosomiasis in Egypt. Trop Geogr Med. 1975;27(4):359-364.
16. Zhu HM, Xiang S, Yang K, Wu XH, Zhou XN. Three Gorges Dam and its impact on the potential transmission of schistosomiasis in regions along the Yangtze River. EcoHealth. 2008;5(2):137-148.
17. Centers for Disease Control &Prevention, Laboratory Identifi cation of Parasites of Public Health Concern. http://www.dpd.cdc.gov/dpdx/images/ ParasiteImages/S-Z/Schistosomiasis/Schistomes-LifeCycle.gif. Accessed November 22, 2009.
18. Lewis F. Schistosomiasis. Curr Protoc Immunol. 2001: Unit 19.1.
19. Georgi JR, Wade SE, Dean DA. Attrition and temporal distribution of Schistosoma mansoni and S. haematobium schistosomula in laboratory mice. Parasitology. 1986;93(pt 1):55-70.
20. Michelson EH. The intermediate snail-host: an agenda for future study. Mem Inst Oswaldo Cruz. 1987;82(suppl 4):193-195.
21. Souza CP. Molluscicide control of snail vectors of schistosomiasis. Mem Inst Oswaldo Cruz. 1995;90(2):165-168.
22. Skelly PJ, Alan Wilson R. Making sense of the schistosome surface. Adv Parasitol. 2006;63:185-284.
23. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106-1118.
24. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002;346(16):1212-1220.
25. Mahmoud AA. Schistosomiasis(bilharziasis): from antiquity to the present. Infect Dis Clin North Am. 2004;18(2):207-218.
26. Davies SJ, McKerrow JH. Developmental plasticity in schistosomes and other helminths. Int J Parasitol. 2003;33(11):1277-1284.
27. Schwartz E. Pulmonary schistosomiasis. Clin Chest Med. 2002;23(2):433-443.
28. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 2009;31(4):163-176.
29. de Jesus AR, Silva A, Santana LB, et al. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis. 2002;185(1):98-105.
30. Quack T, Beckmann S, Grevelding CG. Schistosomiasis and the molecular biology of the male-female interaction of S. mansoni. Berl Munch Tierarztl Wochenschr. 2006;119(9-10):365-372. (Pubitemid 44568053)
31. Boros DL, Whitfield JR. Enhanced Th1 and dampened Th2 responses synergize to inhibit acute granulomatous and fibrotic responses in murine schistosomiasis mansoni. Infect Immun. 1999;67(3):1187-1193.
32. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation. 2008;118(17):1758-1766.
33. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol. 2000;164(5):2585-2591.
34. Warren KS. Hepatosplenic schistosomiasis: a great neglected disease of the liver. Gut. 1978;19(6):572-577.
35. Warren KS. The pathogenesis of "clay-pipe stem cirrhosis" in mice with chronic schistosomiasis mansoni, with a note on the longevity of the schistosomes. Am J Pathol. 1966;49(3):477-489.
36. Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am. 1992;21(1):163-177.
37. Kamal SM, El Sayed Khalifa K. Immune modulation by helminthic infections: worms and viral infections. Parasite Immunol. 2006;28(10):483-496.
38. Mohamed-Ali Q, Elwali NE, Abdelhameed AA, et al. Susceptibility to periportal (Symmers) fibrosis in human schistosoma mansoni infections: evidence that intensity and duration of infection, gender, and inherited factors are critical in disease progression. J Infect Dis. 1999;180(4):1298-1306.
39. Andrade ZA. Pathology of human schistosomiasis. Mem Inst Oswaldo Cruz. 1987;82(suppl 4):17-23.
40. Ferreira PP, Camara EJ, Paula RL, Zollinger CC, Cavalcanti AR, Bittencourt PL. Prevalence of hepatopulmonary syndrome in patients with decompensated chronic liver disease and its impact on short-term survival. Arq Gastroenterol. 2008;45(1):34-37.
41. Andrade ZA, Andrade SG. Pathogenesis of schistosomal pulmonary arteritis. Am J Trop Med Hyg. 1970;19(2):305-310.
42. Pesce JT, Ramalingam TR, Wilson MS, et al. Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog. 2009;5(4):e1000393.
43. de Almeida MA, Andrade ZA. Effect of chemotherapy on experimental pulmonary schistosomiasis. Am J Trop Med Hyg. 1983;32(5):1049-1054. (Pubitemid 13012094)
44. de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis - prospective study. Hepatogastroenterology. 2003;50(54):2028-2030. (Pubitemid 37467987)
45. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30(4):376-385.
46. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54.
47. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressantassociated pulmonary hypertension. Am J Respir Crit Care Med. 1998;158(6):1999-2001. (Pubitemid 29008845)
48. Rudarakanchana N, Flanagan JA, Chen H, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002;11(13):1517-1525.
49. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(12):1340-1348.
50. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol. 1993;46(6):1086-1091.
51. Angelini DJ, Su Q, Yamaji-Kegan K, et al. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296(4):L582- L593.
52. de Cleva R, Herman P, Pugliese V, Zilberstein B, Saad WA, Gama-Rodrigues JJ. Fathal pulmonary hypertension after distal splenorenal shunt in schistosomal portal hypertension. World J Gastroenterol. 2004;10(12):1836-1837. (Pubitemid 38931218)
53. Aragon AD, Imani RA, Blackburn VR, et al. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol. 2009;164(1):57-65.
54. Xiao S, Tanner M, N'Goran EK, et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop. 2002;82(2):175-181.
55. Hou XY, McManus DP, Gray DJ, et al. A randomized, doubleblind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China. Bull World Health Organ. 2008;86(10):788-795.
56. Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop. 2000;77(1):111-131.
57. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928.
58. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol(prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
59. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res. 2001;2(2):90-101.
60. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895-900.
61. Loureiro R, Mendes A, Bandeira A, Cartaxo H, Sa D. Oral sildenafil improves functional status and cardiopulmonary hemodynamics in patients with severe pulmonary hypertension secondary to chronic pulmonary schistosomiasis: a cardiac magnetic resonance study. Circulation. 2004;110(suppl III):572. Paper presented at: American Heart Association; November 7-10, 2004;New Orleans, LA.
62. Bandeira AMP, Mendes A, Loureiro R, et al. Clinical efficacy of oral sildenafil in severe pulmonary hypertension in patients with chronic pulmonary schistosomiasis. Circulation. 2004;110(suppl III): 296. Paper presented at: American Heart Association; November 7-10, 2004; New Orleans, LA.
63. Blaukovitsch M, Zabel P, Hauber HP. Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov. 2009;4(2):142-149.